Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation

NCT00219583 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00219583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2004
Completion date
June 30, 2005
Enrollment
460
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

ejaculation